BCI

• UNSPSC Description:

  BCI ((E)-BCI) is a DUSP6 (dual specificity phosphatase 6) inhibitor. BCI shows anti-inflammatory activity and decreases reactive oxygen species (ROS) production. BCI can be used in inflammatory disease research[1][2].

• Target Antigen:

  Phosphatase

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/bci.html

• Purity:

  99.73

• Solubility:

  DMSO : 125 mg/mL (ultrasonic)

• Smiles:

  O=C1/C(C(NC2CCCCC2)C3=C1C=CC=C3)=C/C4=CC=CC=C4

• Molecular Weight:

  317.43

• References & Citations:

  [1]Korotchenko VN, et al. In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase. Chembiochem. 2014 Jul 7;15(10):1436-45.|[2]Zhang F, et al. DUSP6 Inhibitor (E/Z)-BCI Hydrochloride Attenuates Lipopolysaccharide-Induced Inflammatory Responses in Murine Macrophage Cells via Activating the Nrf2 Signaling Axis and Inhibiting the NF-κB Pathway. Inflammation. 2019 Apr;42(2):672-681.bioRxiv. 2024 Feb 5.|Cells. 2022 Feb 19;11(4):732.|Dis Model Mech. 2023 May 1;16(5):dmm049662.|Int Immunopharmacol. 2024 Sep 30;143(Pt 1):113280.|Kaohsiung J Med Sci. 2022 Dec 16.|Neural Regen Res. 2023.|Cancer Med. 2024 Oct;13(19):e70276.|Cancers (Basel). 2023 Sep 6, 15(18), 4442.|Development. 2023 Feb 13;dev.201090.|Phytother Res. 2023 Mar 3.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  1245792-51-1